Journal of NeuroVirology

, Volume 12, Issue 3, pp 178–189

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

  • Karl Goodkin
  • Benedetto Vitiello
  • William D. Lyman
  • Deshratn Asthana
  • J. Hampton Atkinson
  • Peter N. R. Heseltine
  • Rebeca Molina
  • Wenli Zheng
  • Imad Khamis
  • Frances L. Wilkie
  • Paul Shapshak
Article

DOI: 10.1080/13550280600827344

Cite this article as:
Goodkin, K., Vitiello, B., Lyman, W.D. et al. Journal of NeuroVirology (2006) 12: 178. doi:10.1080/13550280600827344

Abstract

d-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment.

Keywords

CSF clinical trial cognition DAPTA HIV peptide T viral load 

Copyright information

© Journal of NeuroVirology, Inc. 2006

Authors and Affiliations

  • Karl Goodkin
    • 1
    • 2
  • Benedetto Vitiello
    • 3
  • William D. Lyman
    • 4
    • 5
  • Deshratn Asthana
    • 1
  • J. Hampton Atkinson
    • 6
  • Peter N. R. Heseltine
    • 7
  • Rebeca Molina
    • 1
  • Wenli Zheng
    • 1
  • Imad Khamis
    • 1
  • Frances L. Wilkie
    • 1
  • Paul Shapshak
    • 1
    • 8
  1. 1.Departments of Psychiatry and Behavioral Sciences and of Neurology (M836)University of Miami School of MedicineMiamiUSA
  2. 2.Department of NeurologyUniversity of Miami School of MedicineMiamiUSA
  3. 3.Child and Adolescent Treatment and Preventive Intervention Research BranchNational Institute of Mental HealthBethesdaUSA
  4. 4.Children’s Research Center of MichiganChildren’s Hospital of MichiganDetroitUSA
  5. 5.Department of PediatricsWayne State UniversityDetroitUSA
  6. 6.HIV Neurobehavioral Research Center, Department of PsychiatryUniversity of California at San DiegoSan DiegoUSA
  7. 7.Infectious Diseases DivisionQuest Diagnostics Nichols InstituteSan Juan CapistranoUSA
  8. 8.Department of PathologyUniversity of Miami School of MedicineMiamiUSA

Personalised recommendations